Literature DB >> 19549006

Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.

Lilia Marinova-Mutafchieva1, Mona Sadeghian, Lauren Broom, John B Davis, Andrew D Medhurst, David T Dexter.   

Abstract

Cellular interactions between activated microglia and degenerating neurons in in vivo models of Parkinson's disease are not well defined. This time course study assesses the dynamics of morphological and immunophenotypic properties of activated microglia in a 6-hydroxydopamine (6-OHDA) model of Parkinson's disease. Neurodegeneration in the substantia nigra pars compacta (SNc) was induced by unilateral injection of 6-OHDA into the medial forebrain bundle. Activated microglia, identified using monoclonal antibodies: clone of antibody that detects major histocompatibility complex (MHC) class II antigens (OX6) for MHC class II, clone of antibody that detects cell surface antigen-cluster of differentiation 11b - anti-complement receptor 3, a marker for complement receptor 3 and CD 68 for phagocytic activity. Activation of microglia in the lesioned SNc was rapid with cells possessing amoeboid or ramified morphology appeared on day 1, whilst antibody clone that detects macrophage-myeloid associated antigen immunoreactivity was observed at day 3 post-lesion when there was no apparent loss of tyrosine hydroxylase (TH)+ve dopaminergic (DA) SNc neurons. Thereafter, OX6 and antibody clone that detects macrophage-myeloid associated antigen activated microglia selectively adhered to degenerating axons, dendrites and apoptotic (caspase 3+ve) DA neurons in the SNc were observed at day 7. This was followed by progressive loss of TH+ve SNc neurons, with the peak of TH+ve cell loss (51%) being observed at day 9. This study suggests that activation of microglia precedes DA neuronal cell loss and neurons undergoing degeneration may be phagocytosed prematurely by phagocytic microglia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549006     DOI: 10.1111/j.1471-4159.2009.06189.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  73 in total

1.  Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.

Authors:  P J Austin; M J Betts; M Broadstock; M J O'Neill; S N Mitchell; S Duty
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.

Authors:  Chi Wang Ip; Sandra K Beck; Jens Volkmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-20       Impact factor: 3.575

3.  Neurotoxicity to dopamine neurons after the serial exposure to alcohol and methamphetamine: Protection by COX-2 antagonism.

Authors:  Amanda L Blaker; Eric A Rodriguez; Bryan K Yamamoto
Journal:  Brain Behav Immun       Date:  2019-06-20       Impact factor: 7.217

4.  The expression and release of Hsp60 in 6-OHDA induced in vivo and in vitro models of Parkinson's disease.

Authors:  Mei jiang Feng; Ling Zhang; Zhengxia Liu; Ping Zhou; Xiang Lu
Journal:  Neurochem Res       Date:  2013-08-14       Impact factor: 3.996

5.  Treadmill Exercise Prevents Increase of Neuroinflammation Markers Involved in the Dopaminergic Damage of the 6-OHDA Parkinson's Disease Model.

Authors:  Caroline Cristiano Real; Priscila Crespo Garcia; Luiz R G Britto
Journal:  J Mol Neurosci       Date:  2017-08-11       Impact factor: 3.444

6.  Human adipose-derived mesenchymal stem cells improve motor functions and are neuroprotective in the 6-hydroxydopamine-rat model for Parkinson's disease when cultured in monolayer cultures but suppress hippocampal neurogenesis and hippocampal memory function when cultured in spheroids.

Authors:  Jürgen Berg; Manfred Roch; Jennifer Altschüler; Christine Winter; Anne Schwerk; Andreas Kurtz; Barbara Steiner
Journal:  Stem Cell Rev Rep       Date:  2015-02       Impact factor: 5.739

Review 7.  The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Authors:  J Schapansky; J D Nardozzi; M J LaVoie
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

Review 8.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

Review 10.  Microglia-Mediated Inflammation and Neurodegenerative Disease.

Authors:  Ling Xu; Dan He; Ying Bai
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.